

Financial Markets Standards Board Limited, 125 Old Broad Street, London, EC2N 1AR AstraZeneca PLC 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge, CB2 0AA United Kingdom T: +44 (0) 20 3749 5000

astrazeneca.com

21 November 2023

Financial Markets Standards Board – AstraZeneca Statement of Commitment - 2022

AstraZeneca (the 'Company') acknowledges that the Standards published by the Financial Markets Standards Board (whose name changed from FICC Markets Standards Board on 29 April 2022) ("FMSB") represent generally recognised good practice in the wholesale financial markets. The Company confirms that it is committed to conduct its wholesale financial markets activities (its 'Activities') in a manner consistent with the Core Principles contained in FMSB Standards, and to have internal policies, procedures and controls reasonably designed to give effect to those Core Principles where they are applicable to its Activities, in a manner that is commensurate with the nature of its Activities in the relevant entity or jurisdiction.

This Statement of Commitment applies to all Standards published by FMSB in final form prior to 31 December 2022 and reaffirms any previous Statements of Commitment made by the Company where appropriate.

The Company determines that this Statement of Commitment and its reaffirmation applies to the following Standards:

Standard	Final release
Standard for the sharing of investor allocation information in the fixed	15 February 2022
income primary markets	
Standard on use of Term SONIA reference rates	28 July 2021
Standard for the execution of Large Trades in FICC markets	7 May 2021
Secondary Market Trading Error Compensation Standard	28 January 2019
Risk Management Transactions for New Issuance Standard	3 July 2018
New Issue Process standard for the Fixed Income markets	2 May 2017
Reference Price Transactions standard of the Fixed Income markets	21 November 2016

The Standards on Conduct of Participants in LBMA Precious Metal Auctions and Binary Options for the Commodities markets are not relevant because the Company does not undertake such market activities.

The Company will publish this Statement of Commitment on its public website at the following address: <u>www.astrazeneca.com</u>

By signing this Statement of Commitment, the Institution also confirms it agrees to be subject to, and act in accordance with, the FMSB By-laws (as amended from time to time).

The Statement of Commitment is signed by the following on behalf of the Company

Name: Aradhana Sarin

Position: Chief Financial Officer

Signature:

Anadhana lacen

AstraZeneca PLC Registered in England No. 2723534 Registered office: 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge, CB2 0AA United Kingdom